Inclusion Criteria:  Patients> 50 years old diagnosed with neovascular age related macular degeneration, Patients who have never received anti-VEGF treatment, Patients who started intra-vitreous injections of aflibercept between 01 January 2014 and November 30, 2019, Treatment by "treat-and-extend" directly after the loading dose of aflibercept, Availability of the medical file reporting treatment with aflibercept.  Exclusion Criteria:  Participation in an interventional clinical study during treatment with aflibercept, Patients with ocular pathologies who required surgery during the first 24 months of treatment with aflibercept (eg advanced glaucoma or cataracts).